As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: July 23, 2012
by Ransdell Pierson for Reuters:
Pfizer Inc said on Monday its experimental Alzheimer’s disease treatment failed to prove effective in one of four high-stakes late-stage trials of the medicine.
The trial involved individuals who carry a variation of a gene called ApoE4 that makes them far more likely to develop Alzheimer’s disease. Pfizer said it and its partner Johnson & Johnson will continue with three other late-stage trials of their medicine, called bapineuzumab, based upon a review by independent safety monitors.
The failed North American trial was supervised by J&J, which is also heading another Phase III trial in North America involving patients with mild to moderate Alzheimer’s disease that do not carry the ApoE4 gene variation. Pfizer is conducting a pair of overseas Phase III trials, also involving both ApoE4 carriers, and non-carriers.
Bapineuzumab, an injectable monoclonal antibody, works by attacking a protein called beta-amyloid that is believed by many researchers to be a leading cause of Alzheimer’s disease.
Most industry analysts have held out little hope that either the Pfizer/J&J drug, or a similar medicine being develped by Eli Lilly and Co called solanezumab, will succeed in their primary goals of improving cognitive and life-function for such patients that already have symptoms.
Pfizer shares were down 1.5 percent in extended trading to $23.25. U.S. traded shares of Irish drugmaker Elan, which is also a development partner, fell nearly 17 percent to $11.25. J&J shares eased 0.4 percent to $67.82.
Our bodies change as we age – partly due to natural physiological aging and partly due to lifestyle choices. As early as our thirties, we begin to lose a small amount of muscle mass, and,...
Utilizing tau PET imaging, new research finds tau to be a more accurate indication for future neurodegeneration, highlighting its potential for precision medicine-based treatment approaches. Amyloid-β has long been the bane of every Alzheimer’s researcher. Often found in...
It’s never too late to start working on brain health. That said, the strategies for how to optimize your brain will vary depending on several aspects, not the least of which is...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.